Clinical Trial: Study of GT103 in Combination With Pembrolizumab in Refractory, Metastatic Non-Small Cell Lung Cancer
Study Status: Completed
Recruit Status: RECRUITING
Condition: Non Small Cell Lung Cancer
Study Type: INTERVENTIONAL
Official Title: A Phase II Study of GT103 in Combination With Pembrolizumab in Refractory, Metastatic Non-Small Cell Lung Cancer
Brief Summary:
This open-label, non-randomized Phase II trial is designed to assess the safety and tolerability of GT103 in combination with pembrolizumab in adult subjects with relapsed or refractory, metastatic NSCLC.The study will consist of a safety lead-in of 10-20 patients.A total of 50 patients will be treated with the combination at the safest dose of GT103 as determined in the safety lead-in.If 10 additional patients are enrolled to the dose level -1 then the maximum of 60 subjects may be accrued to this trial.
Read more